Metformina para la diabetes mellitus tipo 2. Revisión sistemática y metaanálisis

In the long term metformin reduces the risks of clinical events associated with diabetes. There are no long term clinical trials which compare α-glucosidase inhibitors, meglitinides, and thiazolidinediones with metformin, in primary results. The different treatments compared with metformin did not obtain more benefit for the secondary results evaluated.